Keros Therapeutics’ (KROS) “Neutral” Rating Reiterated at Guggenheim

Guggenheim reiterated their neutral rating on shares of Keros Therapeutics (NASDAQ:KROS) in a research report sent to investors on Friday morning,Benzinga reports.

KROS has been the subject of a number of other research reports. HC Wainwright lowered their price target on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a report on Friday, December 13th. Wells Fargo & Company boosted their price target on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Wedbush reiterated an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, William Blair lowered Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $52.56.

Keros Therapeutics Stock Performance

KROS opened at $10.86 on Friday. The stock has a market cap of $439.94 million, a price-to-earnings ratio of -2.08 and a beta of 1.43. The stock’s 50 day moving average price is $36.37 and its 200-day moving average price is $47.16. Keros Therapeutics has a one year low of $9.77 and a one year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business’s revenue was up 4750.0% on a year-over-year basis. During the same quarter last year, the company posted ($1.33) earnings per share. As a group, analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

Hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its holdings in Keros Therapeutics by 6.8% during the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock worth $42,146,000 after buying an additional 46,041 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Keros Therapeutics by 14.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock valued at $15,105,000 after purchasing an additional 32,492 shares during the last quarter. Barclays PLC lifted its holdings in shares of Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after purchasing an additional 35,022 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Keros Therapeutics during the 3rd quarter valued at $603,000. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.